BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 28741490)

  • 1. In Vivo RNAi Screening for Pancreatic Cancer Drivers: PILOTing the WDR5-MYC Axis.
    Schneider G; Saur D
    Trends Cancer; 2016 Aug; 2(8):391-392. PubMed ID: 28741490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.
    Carugo A; Genovese G; Seth S; Nezi L; Rose JL; Bossi D; Cicalese A; Shah PK; Viale A; Pettazzoni PF; Akdemir KC; Bristow CA; Robinson FS; Tepper J; Sanchez N; Gupta S; Estecio MR; Giuliani V; Dellino GI; Riva L; Yao W; Di Francesco ME; Green T; D'Alesio C; Corti D; Kang Y; Jones P; Wang H; Fleming JB; Maitra A; Pelicci PG; Chin L; DePinho RA; Lanfrancone L; Heffernan TP; Draetta GF
    Cell Rep; 2016 Jun; 16(1):133-147. PubMed ID: 27320920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment.
    Huang Y; Nahar S; Nakagawa A; Fernandez-Barrena MG; Mertz JA; Bryant BM; Adams CE; Mino-Kenudson M; Von Alt KN; Chang K; Conery AR; Hatton C; Sims RJ; Fernandez-Zapico ME; Wang X; Lillemoe KD; Fernández-Del Castillo C; Warshaw AL; Thayer SP; Liss AS
    Clin Cancer Res; 2016 Aug; 22(16):4259-70. PubMed ID: 27169995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.
    Hessmann E; Schneider G; Ellenrieder V; Siveke JT
    Oncogene; 2016 Mar; 35(13):1609-18. PubMed ID: 26119937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated genomic, transcriptomic, and RNA-interference analysis of genes in somatic copy number gains in pancreatic ductal adenocarcinoma.
    Samuel N; Sayad A; Wilson G; Lemire M; Brown KR; Muthuswamy L; Hudson TJ; Moffat J
    Pancreas; 2013 Aug; 42(6):1016-26. PubMed ID: 23851435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.
    Wan C; Gong C; Zhang H; Hua L; Li X; Chen X; Chen Y; Ding X; He S; Cao W; Wang Y; Fan S; Xiao Y; Zhou G; Shen A
    Cancer Lett; 2016 Apr; 373(1):67-76. PubMed ID: 26803058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma.
    Vaz AP; Deb S; Rachagani S; Dey P; Muniyan S; Lakshmanan I; Karmakar S; Smith L; Johansson S; Lele S; Ouellette M; Ponnusamy MP; Batra SK
    Oncotarget; 2016 Jan; 7(3):3317-31. PubMed ID: 26689992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease.
    Murphy SJ; Hart SN; Halling GC; Johnson SH; Smadbeck JB; Drucker T; Lima JF; Rohakhtar FR; Harris FR; Kosari F; Subramanian S; Petersen GM; Wiltshire TD; Kipp BR; Truty MJ; McWilliams RR; Couch FJ; Vasmatzis G
    Cancer Res; 2016 Feb; 76(3):749-61. PubMed ID: 26676757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.
    Beglyarova N; Banina E; Zhou Y; Mukhamadeeva R; Andrianov G; Bobrov E; Lysenko E; Skobeleva N; Gabitova L; Restifo D; Pressman M; Serebriiskii IG; Hoffman JP; Paz K; Behrens D; Khazak V; Jablonski SA; Golemis EA; Weiner LM; Astsaturov I
    Clin Cancer Res; 2016 Dec; 22(24):6153-6163. PubMed ID: 27384421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma.
    You N; Li J; Gong Z; Huang X; Wang W; Wang L; Wu K; Zheng L
    Mol Carcinog; 2017 Feb; 56(2):607-624. PubMed ID: 27350032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long non-coding RNA HOTAIR affects the radiosensitivity of pancreatic ductal adenocarcinoma by regulating the expression of Wnt inhibitory factor 1.
    Jiang Y; Li Z; Zheng S; Chen H; Zhao X; Gao W; Bi Z; You K; Wang Y; Li W; Li L; Liu Y; Chen R
    Tumour Biol; 2016 Mar; 37(3):3957-67. PubMed ID: 26482614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fractalkine/CX3CR1 axis modulated the development of pancreatic ductal adenocarcinoma via JAK/STAT signaling pathway.
    Huang L; Ma B; Ma J; Wang F
    Biochem Biophys Res Commun; 2017 Dec; 493(4):1510-1517. PubMed ID: 28986258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma.
    Deng X; Ewton DZ; Li S; Naqvi A; Mercer SE; Landas S; Friedman E
    Cancer Res; 2006 Apr; 66(8):4149-58. PubMed ID: 16618736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GADD45alpha is highly expressed in pancreatic ductal adenocarcinoma cells and required for tumor cell viability.
    Schneider G; Weber A; Zechner U; Oswald F; Friess HM; Schmid RM; Liptay S
    Int J Cancer; 2006 May; 118(10):2405-11. PubMed ID: 16353139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development.
    Dutruel C; Bergmann F; Rooman I; Zucknick M; Weichenhan D; Geiselhart L; Kaffenberger T; Rachakonda PS; Bauer A; Giese N; Hong C; Xie H; Costello JF; Hoheisel J; Kumar R; Rehli M; Schirmacher P; Werner J; Plass C; Popanda O; Schmezer P
    Oncogene; 2014 Jun; 33(26):3401-10. PubMed ID: 23912455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLAC8 Localizes to the Inner Plasma Membrane of Pancreatic Cancer Cells and Regulates Cell Growth and Disease Progression through Critical Cell-Cycle Regulatory Pathways.
    Kaistha BP; Lorenz H; Schmidt H; Sipos B; Pawlak M; Gierke B; Kreider R; Lankat-Buttgereit B; Sauer M; Fiedler L; Krattenmacher A; Geisel B; Kraus JM; Frese KK; Kelkenberg S; Giese NA; Kestler HA; Gress TM; Buchholz M
    Cancer Res; 2016 Jan; 76(1):96-107. PubMed ID: 26669866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
    Giulietti M; Occhipinti G; Principato G; Piva F
    Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
    Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
    Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.